BACKGROUND: Systemic drugs-like oral montelukast can reach lower airways, whose inflammation plays a crucial role in the evolution of asthma, while inhaled drugs hardly reach them. The impulse oscillometry (IOS) technique is useful to evaluate both central and peripheral airways function. OBJECTIVE: To measure the effect of oral montelukast on airways resistance evaluated by oscillometry in children with asthma. METHODS: In an open study, respiratory function in 23 children with mild asthma and a positive bronchodilator response was assessed by spirometry and oscillometry. They took oral montelukast during 4 weeks and were again evaluated. As a control group, 23 similar patients with no preventive treatment underwent the same study. MEASUREMENTS AND MAIN RESULTS: Children on oral montelukast showed improvements (measured in kPa s L(-1)) in all oscillometry parameters: mean 0.20 (22.4%) in total respiratory impedance Zrs5, 0.18 (21.8%) in total airway resistance Rrs5, 0.09 (17.8%) in central airway resistance Rrs20, and 0.09 (28.8%) in distal capacitive reactance Xrs5; the frequency of resonance Fres improved 2.3 Hz (8.7%) (P<0.05 in all cases). No changes were found in the control group. Expiratory flows showed no changes except for a small (0.23 L s(-1), 7.4%) but significant worsening of FEF25-75 in the control group. CONCLUSIONS:Montelukast improves central and especially peripheral airways function in the first month of treatment, as evaluated by IOS, a technique based on tidal breathing analysis which is more sensitive than conventional forced spirometry.
RCT Entities:
BACKGROUND: Systemic drugs-like oral montelukast can reach lower airways, whose inflammation plays a crucial role in the evolution of asthma, while inhaled drugs hardly reach them. The impulse oscillometry (IOS) technique is useful to evaluate both central and peripheral airways function. OBJECTIVE: To measure the effect of oral montelukast on airways resistance evaluated by oscillometry in children with asthma. METHODS: In an open study, respiratory function in 23 children with mild asthma and a positive bronchodilator response was assessed by spirometry and oscillometry. They took oral montelukast during 4 weeks and were again evaluated. As a control group, 23 similar patients with no preventive treatment underwent the same study. MEASUREMENTS AND MAIN RESULTS:Children on oral montelukast showed improvements (measured in kPa s L(-1)) in all oscillometry parameters: mean 0.20 (22.4%) in total respiratory impedance Zrs5, 0.18 (21.8%) in total airway resistance Rrs5, 0.09 (17.8%) in central airway resistance Rrs20, and 0.09 (28.8%) in distal capacitive reactance Xrs5; the frequency of resonance Fres improved 2.3 Hz (8.7%) (P<0.05 in all cases). No changes were found in the control group. Expiratory flows showed no changes except for a small (0.23 L s(-1), 7.4%) but significant worsening of FEF25-75 in the control group. CONCLUSIONS:Montelukast improves central and especially peripheral airways function in the first month of treatment, as evaluated by IOS, a technique based on tidal breathing analysis which is more sensitive than conventional forced spirometry.
Authors: Erika G Meraz; Homer Nazeran; Carlos D Ramos; Pat Nava; Bill Diong; Michael D Goldman; Christine A Goldman Journal: Biomed Eng Online Date: 2011-03-25 Impact factor: 2.819
Authors: Hanna M Knihtilä; Benjamin J Stubbs; Vincent J Carey; Nancy Laranjo; Su H Chu; Rachel S Kelly; Robert S Zeiger; Leonard B Bacharier; George T O'Connor; Jessica Lasky-Su; Scott T Weiss; Augusto A Litonjua Journal: J Allergy Clin Immunol Date: 2021-01-22 Impact factor: 14.290
Authors: Cláudio Gonçalves de Albuquerque; Flávio Maciel Dias de Andrade; Marcus Aurélio de Almeida Rocha; Alina Farias França de Oliveira; Waldemar Ladosky; Edgar Guimarães Victor; José Ângelo Rizzo Journal: J Bras Pneumol Date: 2015 Sep-Oct Impact factor: 2.624